The current standard of care for hepatitis C infection is peginterferon/ribavirin (PegIFN/RBV). We are entering the era where direct-acting antiviral agents (DAAs) will be added to PegIFN/RBV, leading to higher sustained response rates in genotype 1 infected individuals. Currently DAAs are directed toward specific proteins involved in hepatitis C replication with NS3/NS4A protease inhibitors furthest in development. Telaprevir and boceprevir are both NS3/NS4a inhibitors that significantly improve sustained response when added to PegIFN and RBV. The hepatitis C virus (HCV) polymerase inhibitors are another promising DAA class. These molecules are divided into nucleoside/nucleotide polymerase inhibitors and nonnucleotide/nucleoside polymerase inhibitors. Nucleoside/nucleotide polymerase inhibitors have a high barrier to resistance and appear to be effective across a broad range of genotypes. Nonnucleoside polymerase inhibitors have a lower barrier of resistance and appear to be genotype specifi c. Preliminary data with these compounds are also promising. A third class, NS5A inhibitors, has also shown potent HCV RNA suppression in preliminary studies as monotherapy and with PegIFN and RBV. Combinations of these agents are also entering clinical trials and indeed a preliminary report has demonstrated that the combination of an NS3/4A protease inhibitor and NS5B polymerase inhibitor can effectively suppress virus in genotype 1 individuals. Future studies will concentrate on combinations of direct-acting antiviral agents without and with PegIFN and RBV. Clinicians will need to be familiar with managing side effects as well as resistance as we enter this new era. (Gut Liver 2011;5:406-417) 
INTRODUCTION
The hepatitis C virus (HCV) is the most common blood born infection worldwide, and is a major cause of chronic liver disease leading to death from liver failure or hepatocellular carcinoma. The current paradigm for HCV treatment relies on pegylated interferon (PegIFN) and ribavirin (RBV) as agents that enhance endogenous mechanisms for viral clearance and are dependent on host factors. In patients with genotype 1 HCV infection, which comprises the majority of patients infected in most of the world, including Asia, North America, and Europe, sustained viral response (SVR) rates remain suboptimal with less than half of genotype 1 infected individuals going on to achieve SVR. This has led to a shift in the investigational focus for treatment of HCV towards direct acting anti-viral agents (DAA) or specifically targeted antiviral therapy for HCV (STAT-C) agents. This review will focus on the HCV protease and polymerase inhibitors in development for the treatment of hepatitis C infection, discussing their mechanisms of action, therapeutic advantages and disadvantages, and current status in therapeutic armamentarium for anti-HCV therapy.
REPLICATION CYCLE OF HCV
The HCV is a single-stranded RNA molecule that is approximately 9,600 nucleotides in length. 1 The hepatitis C life cycle is similar to many positive strain RNA viruses and the replication cycle and targets for therapy are shown in Figs 1 and 2.
PROTEASES AS POTENTIAL TARGETS OF ANTI-HCV THERAPY
Preclinical data demonstrated the role of the NS3/4A protease as chimpanzees inoculated with HCV containing defective NS3/4A activity did not demonstrate HCV RNA replication. 2 The initial proof of principle that addition of NS3/4A protease could efficiently and effectively suppress HCV RNA replication was established by administration of the NS3/4A inhibitor BILN2061 for 2 days in genotype 1 patients with chronic hepatitis C, which led to reductions of 100-1,000 fold in all individuals. 3 This molecule BILN2061 did not receive further development due to concerns over cardiac toxicity.
DAA
Telaprevir (VX950; Vertex Pharmaceuticals, Cambridge, MA, USA) and boceprevir (SCH503034; Merck, Kenilworth, NJ, USA) are both peptidomimetic inhibitors of the NS3/4A protease that are currently in phase 3 trials and other agents are in earlier phase trials (Table 1) . Both show substantial potential to favorably impact SVR rates when added to PegIFN and RBV. Telaprevir, a selective peptidomimetic inhibitor of HCV NS3/NS4A Fig. 1 . Hepatitis C virus (HCV) infection and replication: targets for therapy. The virus enters the cell through attachment entry and fusion and undergoes transcription to form a complementary negative sense RNA molecule which serves as the template for positive stranded RNA molecules. This HCV RNA reading frame contains approximately 9,000 nucleotides and generates 3 structural proteins, 6 nonstructural (NS) proteins, and 2 proteins of unclear function. The most advanced therapies in the direct-acting antiviral drug development are directed toward the NS3/NS4A serine protease. The structural proteins are used to assemble new viral particles and the NS proteins support viral RNA replication. The NS3/4A is a serine protease (NS3) and cofactor (NS 4A) that catalyzes the post-translational processing of NS proteins from the polyprotein which is important for viral replication. The NS3 protease cleaves NS4A-NS4B, NS4B-NS5A and NS5A-NS5B junctions. The products released go on to form a replicative complex responsible for forming viral RNA providing an ideal target for anti-viral therapy HCV RNA replication primarily depends upon the RNA dependent/RNA polymerase (NS5B). X-ray crystallography has demonstrated that the NS5B polymerase has a classical fingers, palm, and thumb structure providing multiple areas for therapeutic targets. Another key structure in HCV replication is the NS5A protein, though the mechanisms by which NS5A regulates HCV RNA replication are less clear. It appears to have a key role in formation of the replication complex as well as interact with the NS5B polymerase. Viral assembly and release involves the HCV core protein and to date, therapeutic targets have not shown significant antiviral efficacy. protease forms a covalent, reversible complex with the NS3/4A protease (Fig. 3) . In vitro data with genotype 1b replicons demonstrated a 4 log reduction in HCV RNA level.
Telaprevir 1) Phase 1 studies
An initial phase 1B dose finding study with 14 days of telaprevir monotherapy replicated the in vitro findings. Patients who were both naïve and had failed previous antiviral therapy with PegIFN/RBV were randomized to receive telaprevir or placebo at a dose of 450 mg q8h, 750 mg q8h, or 1,250 mg q12h. 4 The study demonstrated that the 750 mg q8h dose displayed the highest trough plasma concentrations with a median reduction in 14 days of 4 log 10 and HCV RNA became undetectable in 2 individuals. In the other 2 dosing regimens, viral rebound was seen and was later seen to be associated with the development of telaprevir resistant variants. A second phase 1 study confirmed that PegIFN alfa-2a 180 μg could be combined with telaprevir for 14 days at a loading dose of 1,250 mg followed by 750 mg q8h. In this study, 60% of 15 participants who received telaprevir or telaprevir/PegIFN before treatment with standard HCV therapy achieved SVR. 5 2) Phase 2 studies: treatment of naïve patients These phase 1 studies allowed the development of phase 2 telaprevir studies in naïve HCV patients, the Prove 1 and Prove 2 studies. The Prove 1 study, the first North American multicenter telaprevir trial demonstrated the potent antiviral effects of telaprevir 750 mg q8h when given in combination with PegIFN and RBV. 6 To address the issue of resistance, stopping rules were defined as those with an increase in HCV RNA of greater than 1 log compared with nadir or an increase of HCV RNA to greater than 100 IU after undetectability and anyone with detectable HCV RNA by week 24 was discontinued. In this study 40% to 49% of individuals had advanced fibrosis. The SVR was 39% in prior nonresponders with 12 weeks of triple combination therapy followed by 24 weeks of PegIFN/RBV similar to the SVR rate (38%) seen with 24 weeks of telaprevir, PegIFN/RBV followed by 24 weeks of PegIFN/ RBV. Again, the elimination of ribavirin markedly reduced SVR rates with high rates of breakthrough and relapse. In relapsers, the SVR was 69% with 12 weeks of telaprevir, Peg IFN/RBV followed by 12 weeks of PegIFN and RBV and 76% with48-week treatment with 24 weeks of telaprevir, PegIFN/RBV followed by 24 weeks of PegIFN/RBV. In this study, the control group achieved an SVR of 14%. Discontinuation rates again were higher in the telaprevir based arms because of rash (7%). While the cohort was small, 53% of cirrhotic individuals treated with 12 weeks of telaprevir with PegIFN/RBV achieved SVR. Dropout rates were highest in the 48-week treatment arm with 58 of 113 individuals discontinuing therapy suggesting that the optimal duration for telaprevir is 12 weeks, not 24 weeks.
4) Phase 3 studies
Currently, phase 3 is underway and fully enrolled including the Advance trial with 1,050 individuals and Illuminate trial with 500 individuals. There is also the Realize nonresponder trial with 650 individuals. All of these trials will provide further data on the optimal use of telaprevir in those who have not been treated or naïve patients as well as those who failed to achieve SVR.
5) Emergence of drug resistance
While telaprevir and other DAA agents will substantially improve SVR rates, clinicians who treat HCV infection will have to be cognizant of the generation of drug-resistant mutations given the high rate of replication of the HCV virus. Drug-resistant variants may exist as minor viral populations or quasispecies serves as the source of drug resistance. The resistance profiles are listed in Table 2 . Regardless, with the addition of most DAA agents, it is likely that genetic resistant drug resistant mutations are generated immediately but these resistant mutations are typically associated with reduced replicative fitness, and retain sensitivity to PegIFN/RBV.
6) Safety and toxicity
Regarding the safety and toxicity of telaprevir, it is generally well tolerated, though side effects that will require careful management include gastrointestinal side effects including diarrhea, rash, pruritus, and anemia. These adverse events were the most common reasons leading to discontinuation in the telaprevir arms in the phase 2 studies. The rash appears in phase 2 trials to account for approximately 7% of all treatment discontinuations, and pruritus is common. Anemia is also noted with telaprevir as well as other DAA agents such as boceprevir.
Boceprevir 1) Preclinical studies
Boceprevir is peptidomimetic ketoamide HCV NS3 protease inhibitor that binds reversibly to the NS3 active site (Fig. 3) . Malcolm et al. 9 demonstrated a robust anti-viral activity of boceprevir in HCV replicons with treatment resulting in a 1.5 to 2-log drop in RNA levels at 72 hours and a 3.5 to 4-log drop by day 1. Cells treated with boceprevir and PegIFN had a greater HCV replicon suppression than either agent alone and this effect appeared to be additive, rather than synergistic. This promising in vitro data allowed boceprevir to enter clinical trials.
2) Phase 1 studies
The first of these trials was a European phase 1 clinical trial comparing boceprevir monotherapy to PegIFN 2b 1.5 μg/kg weekly and PegIFN plus boceprevir therapy in a nonresponder 3) Phase 2 studies With this preliminary data, a phase 2 dose-finding boceprevir study was initiated to determine the optimal boceprevir dose, whether ribavirin is required in combination with boceprevir, and what the optimal treatment duration would be in a null responder population. 11 In this study, 357 null responders who either failed to achieve EVR or failed to clear virus with >12 weeks PegIFN alfa-2b/RBV therapy were enrolled and treated with PegIFN alfa-2b/RBV plus placebo, PegIFN alfa-2b plus boceprevir in ascending doses (100/200/400/800 mg) t.i.d. or PegIFN alfa-2b boceprevir 400 mg t.i.d. plus RBV. After an interim analysis by the data safety monitoring board (DSMB), the protocol was amended and all responding patients (defined as less than 10,000 IU/mL on original therapy) were assigned to receive PegIFN/RBV and boceprevir 800 t.i.d. for 24 weeks. While the overall SVR rate was low, this trial established several important concepts in the treatment of HCV nonresponders with boceprevir. For treatment of null responders, ribavirin is required for optimal response. Boceprevir dose of 800 mg t.i.d. was safe when given in combination with ribavirin for 24 weeks (no patient initially received this dose). Finally, the null responders randomized to the PegIFN and RBV without boceprevir arm (control) who demonstrated interferon responsiveness (1-2 log reduction at week 13) were more likely to go on to achieve SVR with addition of boceprevir. These preliminary results led to the phase 2 clinical trial HCV Serine Protease Inhibitor Therapy-1 (SPRINT-1) evaluating boceprevir in combination with PegIFN and RBV in HCV genotype 1 treatment naïve patients. 12 In this multi-arm trial, genotype 1 subjects were randomized to receive PegIFN alfa-2b 1.5 μg/ kg (P), weight based RBV and boceprevir (B) 800 mg t.i.d. for 28 or 48 weeks, or a lead-in strategy with 4 weeks of PegIFN/ RBV followed by boceprevir 800 mg t.i.d. addition to PegIFN/ RBV, and these treatment arms were compared to standard therapy of PegIFN/RBV for 48 weeks. The rationale for the leadin strategy was based on the following hypothesis: PegIFN/RBV reach steady-state concentrations by week 4, and with the lead in strategy, patients will have the protease inhibitor added when backbone drug levels have been optimized and the patient's immune system activated, minimizing the period of time with a "functional monotherapy," potentially reducing the likelihood for the development of resistance to boceprevir (or other DAA). This strategy may also reduce the likelihood of the development of resistance by identifying patients who are responders to IFN and RBV prior to their receiving a protease inhibitor or other DAA drug. Approximately 100 subjects were enrolled in each arm and stratified for cirrhosis and African American race. Compared to PegIFN/RBV, significantly more patients in the triple therapy groups achieved SVR In the 28 week treatment arms, SVR rates were 54% and 56% in the non-lead-in and lead-in arms, and in the 48 week treatment arms, SVR rates were 67% and 75% for non-lead-in and lead-in arms. Reducing the dose of RBV reduced the hematologic toxicity (anemia), but similar to telaprevir, reduced SVR rates with high rates of breakthrough due to resistance. Those who cleared virus at week 4 of boceprevir had high rates of SVR when treated for just 28 weeks. Finally, response rates in African Americans, who typically have poor response to standard therapy, were as high as 53%. Patients with cirrhosis went on to SVR at rates as high as 67%.
4) Phase 3 trials
The recently reported phase 3 Sprint-2 and Respond-2 phase 3 trials give us further insight into the optimal use of boceprevir in combination with PegIFN/RBV in genotype 1 infected individuals. Sprint-1 enrolled 1,094 treatment naïve (938 nonblack cohort and 159 black cohort) patients into 3 treatment arms: 1) 48 weeks of PegIFN/RBV (control), a response-guided therapy (RGT) arm, with 4-week lead-in followed by boceprevir for 24 weeks with an additional 20 weeks of PegIFN/RBV if HCV RNA was detected during weeks 8 through 24. 13 In the third arm, patients received a PegIFN/RBV lead-in, followed by 44 weeks of PegIFN/RBV, and boceprevir. In both cohorts, higher sustained response rates were seen in the boceprevir-containing regimens, with the sustained response rates in the nonblack arm being 67% for the RGT arm and 68% for the 44-week boceprevir/peg/ ribavirin arm. This was superior to PegIFN/RBV control of 40%. Superior sustained response rates were also seen in the black cohort where the response-guided therapy arm achieved an SVR of 42%, with the peg/ribavirin/boceprevir 44-week arm achieving an SVR of 53%, both superior to the control peg/ribavirin of 23%. The nonresponder Respond-2 trial had a comparable design but had a longer duration of boceprevir therapy of 32 weeks in the response guided arm.
14 Patients received either PegIFN alfa-2b and ribavirin control or a 4-week lead-in followed by 32 weeks of boceprevir, PegIFN/RBV with an additional 12 weeks PegIFN/RBV in slow responders vs 44 weeks of PegIFN/ RBV/boceprevir after the 4-week lead-in. This nonresponder study included historical relapsers and partial responders (>2 log reduction week 12), but historical null responders (<2 log reduction after 12 weeks of PegIFN/RBV) were excluded. Again, superior SVR rates were seen with the boceprevir-containing regimens, with 59% of response-guided therapy individuals achieving SVR and 67% of individuals who received boceprevir for 44 weeks of peg/ribavirin after the lead-in achieving SVR. Boceprevir has now been approved for the treatment of naïve patients and nonresponders in combination with PegIFN and RBV in the United States.
5) Safety and toxicity
Anemia and dysguesia were the most significant side effects noted in the boceprevir arms, though those who became anemia had higher SVR rates. The use of erythropoietin (EPO) was permitted in this trial and higher SVR rates were noted in those who developed anemia and required EPO. The role of EPO with boceprevir is currently being studied in a randomized trial that is fully enrolled. The resistance profile of boceprevir is shown in Table 2 and is similar to that of telaprevir.
Other protease inhibitors are currently in development
The NS3/NS4A protease inhibitor ITMN-191 (R7227, danoprevir) (Intermune, Roche) is a selective inhibitor of the NS3/ NS4 protease. As a monotherapy, ITMN-191 led to reductions in plasma HCV RNA in a phase 1B ascending dose study from 100 mg q12h to 200 mg q8h and 300 mg q12h. In this study, maximal decreases in HCV RNA were noted in a 3.9 log 10 and 3.2 log 10 in those receiving danoprevir 200 mg q8h and 200 mg q12h. 15 This study was followed by a preliminary presentation demonstrating robust HCV RNA decline with danoprevir PegIFN 2a/RBV over 14 days with undetectable HCV RNA in up to 57% of individuals receiving danoprevir 300 mg t.i.d. 16 Because a phase 2 study with danoprevir 900 mg twice a day demonstrated Grade IV hepatotoxicity, a pilot study has been reported, demonstrating that ritonavir-boosted danoprevir; with, PegIFN/ RBV could lead to high rates of HCV RNA clearance with no hepatotoxicity. In this pilot study, 30 individuals were randomized to receive danoprevir 100 mg or 200 mg b.i.d. or daily with PegIFN/RBV. Indeed, 100% of individuals clearing HCV RNA in those who receive danoprevir 200 mg b.i.d. with ritonavir boosting 100 mg b.i.d. 17 As ritonavir boosting has been successfully used in the HIV treatment, it may also serve as a useful adjunct to reduce HCV protease exposure and minimize toxicity. The NS3/NS4 protease, TMC-435 (Medavir Incorporated) has also been shown to be effective in treatment of genotype 1 hepatitis C when given in combination with PegIFN and RBV. The initial study of TMC-435 is a macrocyclic HCV NS3/NS4A protease inhibitor, with a favorable pharmacokinetic profile supporting once daily dosing. A small pilot study demonstrated a median of 3.9 log 10 reduction in HCV RNA after 5 days of monotherapy in individuals who had failed previous interferonbased therapy. 18 A phase 2A study with TMC435 (Opera 1) has been reported. In this study, TMC435, was combined in ascending doses from 75 mg to 200 mg for 4 weeks, in combination with PegIFN/RBV in treatment naïve and treatment experienced individuals (nonresponders and relapsers). At week 4, 44%, 78%, and 70% of individuals in the 75, 150, and 200 mg daily treatment groups, achieved plasma HCV RNA levels of <25 IU, with relapsers responding with higher rates of HCV RNA clearance than nonresponders. TMC435 was well tolerated, though elevated serum bilirubin levels (total direct and indirect), primarily with the 200 mg dose were noted. 19 Current studies are ongoing with TMC in combination with PegIFN alfa-2a and ribavirin in the Pillar study and Aspire study, and we await further results for this promising compound which can be given daily. The preliminary resistance profile is listed in Table 2 , with mutations at NS3 amino acid position 80, 155, 156, and 158 being reported. The NS3 protease inhibitor BI201335 is a potent HCV NS34A inhibitor with preliminary results demonstrating improved viral clearance rates through week 12. In the Silen-C1 study, BI201335 was added to PegIFN2a180/RBV at doses of 240 and 120 mg daily in treatment naïve patients. In this study, RVR rates ranging from 90% to 92% (dose independent) and complete EVR ranging from 84% to 91% were noted. 20 The Silen-C2 study used higher doses of BI201335 (240 mg and 240 mg b.i.d.) in combination with PegIFN/RBV in nonresponders who failed previous PegIFN/RBV. The 12-week analysis was recently presented with RVR rates of 62% to 69% seen in the 240 b.i.d. with 3-day PegIFN/RBV lead-in and EVR rates ranging from 54% to 59%. 21 Similar to the Silen-1 study, an increased incidence of jaundice and rash were noted. The final SVR rates for these 2 studies is currently being awaited. Amino acid changes were most commonly seen as residues 168, 156, and 155.
POLYMERASES AS POTENTIAL TARGES OF ANTI-HCV THERAPY 1. NS5B polymerase inhibitors
The HCV replication process is complex and therefore offers a wide variety of targets for antiviral intervention other than the NS3/NS4 protease. As a class, the development of inhibitors of NS5b is not as mature as that of the NS3/NS4a protease inhibitors. Nonetheless, preliminary data suggest that this will be an effective class of agents in the treatment of HCV infection. In contrast to NIs, the heterogeneous class of nonnucleoside inhibitors (NNIs) bind to different allosteric enzyme sites, which results in conformational protein change before the elongation complex is formed. NNIs achieve NS5B inhibition by binding to 1 of multiple allosteric enzyme sites resulting in conformational changes of the protein-inhibiting catalytic activity of polymerase. [22] [23] [24] [25] They have genotype-specific activity and potential for rapid selection of resistance. The rapid development of resistant mutants is possible with non-nucleoside inhibitors because they bind distantly to the active center of NS5B and mutations at the non-nucleoside inhibitor binding site may not necessarily lead to impairment of the enzyme function. Due to their distinc-tive binding sites, different polymerase inhibitors could theoretically be used in combination to reduce the risk of development of resistance (Table 3 , Fig. 4 ).
1) Nucleoside inhibitors
(1) RG7128 RG7128 is the oral prodrug of PSI-6130, a second cytidine nucleoside analogue under clinical development and has demonstrated potent in vitro activity regardless of race, ethnicity and genotype. Thus far, viral resistance has not been detected in any clinical trials with RG7128, which suggests that the nucleoside class may offer a higher genetic barrier to viral resistance than the protease class of inhibitors. In a dose-escalating phase 1b trial, a dose-dependent decrease in HCV RNA was observed in genotype 1 previous nonresponders. 26 RG7128 is well tolerated as monotherapy and no serious AEs were reported in any study arm. In treatment naïve genotype 1 patients, the combination of R7128 (1,500 mg b.i.d. in combination with PegIFN/ RBV achieved a reduction in HCV RNA of approximately 5 log 10 at 4 weeks translating into a RVR rate of 85% (vs 2 log 10 IU/ mL and 10% in control arm). 27 No virological rebound was observed during R7128 treatment to 4 weeks. Importantly, R7128
was generally well tolerated in combination with PegIFNa and RBV. The grade 3/4 hematological toxicity was rare and headache, fatigue, and chills were classified as mild AEs. Preliminary resistance testing failed to identify any variants to week 4 and this trial is ongoing. The combination of a potent anti-viral effect and satisfactory toxicity profile makes R7128 an attractive agent.
In addition, it is the first polymerase inhibitor being tested for anti-viral activity against genotypes 2 and 3 HCV. A small study done recently showed higher SVR with RG7128 plus PegIFNa/RBV in genotypes 2 and 3 HCV patients who previously failed PegIFNa/RBV treatment. 28 This randomized trial comparing RG7128 (n=20) with placebo (n=5), each in combination with PegIFN/RBV for 4 weeks followed by continued PegIFN/ RBV treatment for a total of 24 to 48 weeks, depending on the patient's previous response to therapy and achievement of RVR in the current trial. The RVR rate was 95% with RG7128 triple therapy vs 60% with PegIFNa/RBV and the SVR rates were 65% vs 60%, respectively. Higher SVR rates with RG7128 treatment were associated with achieving RVR and longer duration of PegIFNa/RBV therapy, whereas HCV genotype did not impact the likelihood of SVR with 63% of genotype 2 patients with achieving SVR vs 67% of patients with genotype 3. The higher RVR rates but similar SVR rates with RG7128 triple therapy vs PegIFNa/RBV in this study suggest that polymerase inhibitor treatment will need to be administered for longer than 4 weeks in previous nonresponders with genotype 2 and particularly genotype 3 infection. The novel study INFORM-1, the first dual combination clinical trial with oral antivirals in HCV patients evaluated the safety and combined antiviral activity of RG7227, a protease inhibitor and RG7128, a polymerase inhibitor, in 14 days of combination therapy in treatment-naïve patients, experienced non-null or null-responders infected with HCV genotype 1. 29 The basis of this trial is that induction therapy with potent DAA regimens could potentially enhance the efficacy and decrease the duration of treatment with the current treatmentfor chronic hepatitis C (PegIFN/RBV). Patients receiving this combination for 14 days experienced a median reduction in viral levels of 4.8 to 5.2 log 10 IU in the higher doses tested and this combination was equally effective in both naïve and previous nonresponders with the lowest reductions observed in treatment-naïve patients receiving the lowest drug doses and in previous nonresponders (excluding null responders). The highest end-of-treatment response rate in treatment-naïve individuals (100%) was achieved in patients treated with the highest dosage combination of RG7128/ RG7227 (1,000/900 mg b.i.d.). All patients achieved an RVR at week 4 of treatment with PegIFN/RBV were assigned to an abbreviated 24-week regimen. These encouraging results provide a proof of concept that, when given at optimal doses, a short course of dual combination therapy can be highly effective in suppressing HCV RNA in the absence of PegIFN/RBV. Importantly, no drug resistant mutations emerged during the 14-day treatment period in any patient group. No treatment-related serious adverse events, dose reductions, drug-drug interactions or discontinuations were reported. Given these encouraging data, combinations of DAA agents in the absence of PegIFN and/or RBV will be undertaken. (Fig. 4) BILB1941, BI207127, and MK3281 are NNI-site 1 inhibitors which have been investigated in clinical phase 1 trials and exhibit low to medium anti-viral activities. [32] [33] [34] No selection of resistant variants and viral breakthrough has been observed during 5 days of treatment with BILB1941 or BI207127. Gastrointestinal intolerance at higher doses, elevated liver enzymes, and its liquid formulation led to a halt in further development of BILB1941. In a recent double-blind placebo-controlled study, 7 days of MK-3281 monotherapy in genotype 1/3 HCV male patients resulted in rapid and significant HCV RNA reductions vs placebo with the greatest degree of virologic suppression in genotype 1b HCV patients and no serious clinical or laboratory adverse events were reported.
2) NNI-site 2 inhibitors (thumb 2/thiophene site) (Fig. 4 ) Filibuvir (PF-00868554) is a NNI-site 2 inhibitor with moderate anti-viral activity in a phase 1 study. In a subsequent trial viral breakthrough was observed in 5 of 26 patients during combination therapy with PegIFN-a 2a and RBV for 4 weeks. 35 A phase 2, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of filibuvir plus PegIFN-a 2a/RBV in treatment-naïve, HCV genotype 1 infected subjects is currently underway. Other NNI-site 2 inhibitors which were evaluated in phase 1 trials are VCH-759, VCH-916, and VCH-222. Like during treatment with filibuvir, VCH-759 and VCH-916 application resulted in viral breakthroughs with selection of resistant variants, indicating a lower genetic barrier to resistance of these agents as opposed to the NIs. Preliminary results from a randomized, placebo-controlled phase Ib/IIa dose-escalation study of the novel nonnucleoside HCV NS5B polymerase inhibitor VX-222 were recently reported. 36 VX-222 monotherapy was associated with >3.0 log 10 IU/mL mean decreases in HCV RNA from baseline to day 3 at all doses evaluated, suggesting that this agent represents one of the most potent nonnucleoside polymerase inhibitors tested to date. Reductions in HCV RNA levels were observed within 1 day of VX-222 initiation in all cohorts, including in patients infected with genotypes 1a and 1b HCV. This finding is important because nonnucleoside polymerase inhibitors often have differential activity toward HCV genotypes 1a and 1b. The most frequent adverse events included diarrhea headache and nausea with no serious adverse events were reported.
3) NNI-site 3 inhibitors (palm 1/benzothiadiazine site) ANA598 is a NNI-site 3 inhibitor which displayed antiviral activity during treatment of HCV genotype 1 infected patients when combined with PegIFN/RBV. 37 39 Recent data on the pharmacokinetic profile, safety, and efficacy of ABT-333 treatmentnaïve patients infected with genotype 1 HCV is promising and is being investigated further in combination with PegIFN/RBV. The NNI site 4 inhibitor GS-9190 displays anti-viral activity in a clinical study and variants conferring resistance were identified in the beta-hairpin of the polymerase. 40, 41 Preliminary data of 23 study participants who received multiple ascending doses over 8 days suggested that GS 9190 may be associated with QT prolongation. After consultation and a separate dose-ranging study in healthy volunteers, the QT prolongation at a lower dose of the drug was determined to be "clinically manageable" (Gilead Quarterly Report, May 2, 2008). GS-9190 is currently the most advanced NS5B polymerase NNI (phase 2) and a study in combination with PegIFN/RBV is currently underway with results to be reported in the next year.
NS5A inhibitors
The function of HCV NS5A is not fully defined. Two potent NS5A specifically targeted antiviral therapy compounds have been evaluated in clinical trials, including compounds A-832 (phase 1) and BMS-790052 (phase 2). BMS-790052 binds to domain I of the NS5A protein, which was shown to be important for regulation of HCV replication. It is highly potent selective inhibitor of NS5A, and has shown strong activity against several genotypes in both replicon and JFH-1 systems. 42 The in vitro potency is extremely high with a half maximal effective concentration in the range of 9-127 pM, depending on the viral genotype. This value reflects 100-to 1,000-fold higher potency than most other drugs that are being investigated. The results of a previous single ascending-dose study of BMS-790052 in patients infected with genotype 1 HCV were striking in that patients who received a single 100-mg dose exhibited an approximately 3.6 log 10 mean reduction in HCV RNA that was maintained 144 hours after dosing. 43 A week 12 data from a randomized, placebo-controlled, phase IIa trial investigating different once-daily BMS-790052 doses (3 mg, 10 mg, and 60 mg) in combination with PegIFNa/RBV for 48 weeks in treatmentnaïve patients infected with genotype 1 HCV was recently reported. 44 The preliminary results study (n=48) demonstrated high RVR rates of 92% and 83% with BMS-790052 doses of 10 mg and 60 mg, respectively, in combination with PegIFNa/ RBV. Complete EVR rates were similarly high at 83% in both the 10-mg and 60-mg dosing arms. Patients treated with BMS-790052 3 mg daily experienced lower RVR and complete EVR rates of 42% and 58%, respectively. The adverse event profile at this early stage appears favorable. This preliminary analysis suggests that this drug class may be promising for patients with genotype 1 HCV and it is hoped that similar efficacy will be observed across other genotypes. The resistance profile of BMS-790052 is well characterized in replicon systems but there is limited data from the preliminary clinical trials. Other NS5A inhibitors such as PPI-461 and AZD 7295 are also in clinical development phase and results look encouraging. 45, 46 No clinical data on resistance to this class of drugs have been presented yet and results of multiple dose and combination therapy studies have to be awaited.
CONCLUSION AND FUTURE DIRECTIONS
In summary, it is very likely that the NS3/NS4a protease inhibitors will be approved next year by regulatory agencies in the United States and Europe for use in combination with PegIFN/RBV. This will dramatically improve SVR rates but in those who are poorly interferon responsive, the risk of resistance will remain. Preliminary results suggest that the addition of nucleoside polymerase inhibitors to PegIFN/RBV will also lead to high SVR rates and the nucleoside polymerase inhibitor class may be a particularly attractive backbone therapy for the treatment of hepatitis C. Finally, preliminary data with the NS5a inhibitor class appears to be highly promising when given in combination with PegIFN and RBV. In the future, combination of DAAs including polymerase inhibitors both nucleoside, and nonnucleoside, protease inhibitors, and NS5a inhibitors to PegIFN, and RBV will likely significantly reduce resistance rates, and it is anticipated that the combinations of DAAs will improve SVR rates further in combination with PegIFN and RBV likely by reducing the risk of developing resistance. Moving forward, the ability to eliminate IFN and/or RBV in the future and still achieve SVR will be the next major goal in the treatment of hepatitis C.
